跳至主要内容
临床试验/NCT06994962
NCT06994962招募中不适用

Development and Initial Testing of a Multi-Component Breath Alcohol-Focused Intervention for Young Adults, Stage 3

Northeastern University1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2025年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
90
试验地点
1
主要终点
Technology utilization

研究概览

简要总结

This is the third stage of a three-stage, NIH-funded study to develop and test a multi-modal intervention concerning blood/breath alcohol concentration for young adults who drink heavily. The multimodal intervention will be made up of brief telehealth counseling and psychoeducation and use of three existing mobile technologies. The brief counseling/psychoeducation and mobile technologies provide personalized feedback regarding blood or breath alcohol content. The long-term goal of use of these mobile technologies will be to facilitate moderate drinking. However, the main goals of the proposed research are to learn more about feasibility of our procedures, perceived value of the technologies and ease of use from the research participants' points of view. In this third stage of the study, the investigators will conduct a randomized controlled trial building on the formative research conducted in Stages 1 and 2.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 25 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Be between the ages of 18-25
  • •Be able to read English and complete study evaluations
  • •Report at least four days with heavy episodic drinking (i.e., 4 or more drinks for women and 5 or more drinks for men) out of the prior 30 days
  • •Report having consumed at least one alcoholic drink during a minimum of 12 days out of the prior 30 so that subjects will have multiple opportunities to use the moderate drinking technologies during the intervention period.
  • •Meet, at minimum, DSM-5 criteria for a mild alcohol use disorder (i.e., meet at least 2 diagnostic criteria)
  • •Self-report interest in using a smartphone app to help reduce drinking with a score of at least 3 on a 0-10 scale indicating at least a degree of openness to using technology to moderate drinking.

排除标准

  • •No subject may:
  • •Have been in inpatient or intensive outpatient treatment within the past 12 months
  • •Have used a smartphone application to facilitate moderate drinking more than 1 time within the past 12 months
  • •Meet DSM-5 criteria for current substance use disorder with the exception of tobacco use disorder, mild or moderate alcohol use disorder or mild cannabis use disorder.
  • •History of alcohol withdrawal or medically-assisted detoxification as individuals with this history will likely be in need of more intensive treatment than is offered in this study.
  • •Be psychotic or otherwise severely psychiatrically disabled
  • •Report a history of a medical condition that would contraindicate the consumption of alcohol (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, and gastrointestinal disorders).

研究组 & 干预措施

Moderate drinking technologies with "lower tech" facilitation

Experimental

Brief motivational-interviewing-based counseling followed by use of three moderate drinking technologies (breath alcohol device and app, blood alcohol content estimator app and self-texting procedure) with "lower tech" facilitation.

干预措施: Alcohol-related mobile health technologies (Device)

Moderate drinking technologies with "lower tech" facilitation

Experimental

Brief motivational-interviewing-based counseling followed by use of three moderate drinking technologies (breath alcohol device and app, blood alcohol content estimator app and self-texting procedure) with "lower tech" facilitation.

干预措施: Motivational interview and psychoeducation on blood/breath alcohol concentration (Behavioral)

Moderate drinking technologies with "lower tech" facilitation

Experimental

Brief motivational-interviewing-based counseling followed by use of three moderate drinking technologies (breath alcohol device and app, blood alcohol content estimator app and self-texting procedure) with "lower tech" facilitation.

干预措施: Lower tech facilitation (Behavioral)

Moderate drinking technologies with "higher tech" facilitation

Experimental

Brief motivational-interviewing-based counseling followed by use of three moderate drinking technologies (breath alcohol device and app, blood alcohol content estimator app and self-texting procedure) with "higher tech" facilitation

干预措施: Alcohol-related mobile health technologies (Device)

Moderate drinking technologies with "higher tech" facilitation

Experimental

Brief motivational-interviewing-based counseling followed by use of three moderate drinking technologies (breath alcohol device and app, blood alcohol content estimator app and self-texting procedure) with "higher tech" facilitation

干预措施: Motivational interview and psychoeducation on blood/breath alcohol concentration (Behavioral)

Moderate drinking technologies with "higher tech" facilitation

Experimental

Brief motivational-interviewing-based counseling followed by use of three moderate drinking technologies (breath alcohol device and app, blood alcohol content estimator app and self-texting procedure) with "higher tech" facilitation

干预措施: Higher tech facilitation (Behavioral)

Alcohol Education Condition

Active Comparator

Brief session administering non-personalized information about alcohol followed by the option to receive educational alcohol-related information via text

干预措施: Alcohol Education (Behavioral)

Alcohol Education Condition

Active Comparator

Brief session administering non-personalized information about alcohol followed by the option to receive educational alcohol-related information via text

干预措施: Alcohol Education Technology (Device)

结局指标

主要结局

Technology utilization

时间窗: 4-week field use period

Percentage of reported drinking days on which one reports that moderate drinking technology use has occurred

Acceptability

时间窗: 4-week field use period

Score on acceptability subscale of Modified System Usability Scale

Usability

时间窗: 4-week field use period

Score on acceptability subscale of Modified System Usability Scale

次要结局

  • Drinks per drinking day(4-week field use period)
  • Estimated blood alcohol content(4-week field use period)
  • Negative Consequences(4-week field use period)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
A phase III trials program exploring the integration of Bevacizumab, Everolimus (RAD001), and Lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer - GeparQuintobreast cancer, primary systemic therapy
EUCTR2006-005834-19-DEGBG Forschungs GmbH2,727
进行中(未招募)
1 期
Ensayo clínico en fase III multicéntrico, doble ciego, aleatorizado y con control activo para evaluar la seguridad y la eficacia de raltegravir (MK-0518) administrado una vez al día frente a raltegravir administrado dos veces al día, cada uno en combinación con TRUVADA?, en pacientes infectados por el VIH no tratados previamente A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK-0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA?, in Treatment-Naïve HIV Infected Patients - Safety and efficacy of once daily raltegravir compared to twice daily raltegravirinfección VIH HIV infectionMedDRA version: 11 Level: PT Classification code 10020161 Term: <Manually entered code. Term in E.1.1>
EUCTR2008-002733-70-ESMerck & Co., Inc.750
Unknown
3 期
TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical TrailHR-positive,HER2-negative in Advanced Breast Cancer
NCT05375461Chia Tai Tianqing Pharmaceutical Group Co., Ltd.287
进行中(未招募)
3 期
Study of Vimseltinib for Tenosynovial Giant Cell TumorTenosynovial Giant Cell Tumor, DiffuseTenosynovial Giant Cell TumorTenosynovial Giant Cell Tumor, LocalizedPigmented Villonodular SynovitisGiant Cell Tumor of Tendon Sheath
NCT05059262Deciphera Pharmaceuticals, LLC123
已完成
3 期
Phase III Investigator-Initiated Trial to Investigate Safety and Efficacy of Edoxaban in Patients with Chronic Thromboembolic Pulmonary HypertensioChronic Thromboembolic Pulmonary HypertensionCTEPH, DOAC, warfarin
JPRN-jRCT2071200098Abe Kohtaro74